Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 15/20 | 0.66 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | METAP2 | P50579 | 1/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.38 |
| ▸ | TERT | O14746 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3492535 | 0.79 | GSK3B (1.00) | GSK3BNPC1MAPTRAB9AMETAP2 | |
| SCHEMBL3493961 | 0.78 | GSK3B (0.68) | GSK3BNPC1MAPTRAB9AMETAP2 | |
| SCHEMBL3492383 | 0.78 | GSK3B (0.68) | GSK3BNPC1MAPTRAB9AMETAP2 | |
| SCHEMBL3491254 | 0.78 | GSK3B (1.00) | GSK3BNPC1MAPTRAB9ATERT | |
| SCHEMBL3494028 | 0.76 | GSK3B (0.66) | GSK3BNPC1MAPTRAB9AMETAP2 | |
| SCHEMBL3491930 | 0.73 | GSK3B (0.61) | GSK3BNPC1MAPTRAB9ADYRK1A | |
| SCHEMBL3490598 | 0.71 | GSK3B (0.68) | GSK3BNPC1MAPTRAB9AMETAP2 | |
| SCHEMBL3493208 | 0.71 | GSK3B (1.00) | GSK3BTERT | |
| SCHEMBL3491210 | 0.71 | GSK3B (1.00) | GSK3BNPC1MAPTRAB9A | |
| SCHEMBL3491221 | 0.68 | GSK3B (0.60) | GSK3BDYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8492378-B2 | GSK-3β inhibitor | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-07-23 | — | — | US | disclosed |
| US-20100069381-A1 | GSK-3BETAINHIBITOR | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069381-A1 | GSK-3BETAINHIBITOR | GSK3B, GSK3A, GSKIP | GSK3B 1/4885NPC1 1571/4885MAPT 368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.